Starboard supports Abcam running full sale process
PremiumThe FlyStarboard supports Abcam running full sale process
1y ago
Abcam backs FY 23 revenue view, sees FY24 revenue up 11.3%-13.4% vs. 2019
Premium
The Fly
Abcam backs FY 23 revenue view, sees FY24 revenue up 11.3%-13.4% vs. 2019
1y ago
Abcam to explore strategic alternatives, including sale of company
Premium
The Fly
Abcam to explore strategic alternatives, including sale of company
1y ago
Abcam an ‘interesting candidate’ for buyout, says RBC Capital
PremiumThe FlyAbcam an ‘interesting candidate’ for buyout, says RBC Capital
1y ago
Abcam in discussions on potential sale, Bloomberg reports
Premium
The Fly
Abcam in discussions on potential sale, Bloomberg reports
1y ago
Abcam jumps 14% to $21.73 after disclosing multiple strategic inquiries
Premium
The Fly
Abcam jumps 14% to $21.73 after disclosing multiple strategic inquiries
1y ago
Abcam price target raised to $23 from $21.50 at RBC Capital
PremiumThe FlyAbcam price target raised to $23 from $21.50 at RBC Capital
1y ago
Abcam, Lunaphore enter co-marketing agreement for primary antibodies
Premium
The Fly
Abcam, Lunaphore enter co-marketing agreement for primary antibodies
2y ago
Abcam price target lowered to $17 from $19 at Deutsche Bank
Premium
The Fly
Abcam price target lowered to $17 from $19 at Deutsche Bank
2y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100